Epithelial Cell Cytology in Breast Cancer Risk Assessment
Customize your policy alerts
Sign up for mutualofomaha Policy AHS-G2059 alerts
Get alerted when Policy AHS-G2059 changes without checking for updates manually.
Monitor payer policy activity
This policy addresses coverage of nipple aspiration, ductal lavage, fine-needle aspiration, and related cytologic analysis of breast epithelial cells when used to diagnose, screen for, or assess breast cancer risk.
Epithelial cell cytology used to diagnose, screen for, or assess risk of developing breast cancer does not meet coverage criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.